Skip to main content

Table 3 Summary of TEAEs (safety population)

From: Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study

TEAEs Number of cases (%)
Total number of TEAEs 51
TEAEs
 Grade 1 23 (51)
 Grade 2 17 (38)
 Grade 3 5 (11)
 Grade 4 6 (13)
TEAEs leading to treatment discontinuation 2
Deaths 4
 Treatment-related 1
Treatment-related TEAEs reported in > 1 patient
 Sensory neuropathy 8 (18)
 Myalgia 6 (13)
 Fatigue 4 (9)
 Neutropenia 4 (9)
 Anorexia 2 (4)
 General weakness 2 (4)
 Headache 2 (4)
 Insomnia 2 (4)
 Pneumonia 2 (4)
 Sepsis 2 (4)
 Tinnitus 2 (4)
 Urticaria 2 (4)
  1. Values are expressed as n (%)
  2. TEAE treatment-emergent adverse event